As with any small cap research company, the promise is strong but the research time can be long. Therefore updates on how the research is going are necessary so that stockholders and the investment community don’t forget that the company has promise and is working on something important.
Yesterday, Genta Inc. (OTCBB:GNTA) did just that. It announced its progress on the clinical trials of its promising melanoma drug, Genasense®. This drug may also have broader applications in other cancers as well, since “Genasense® inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense® may enhance the effectiveness of current anti-cancer treatments. Genta is pursuing a broad clinical development program with Genasense®, evaluating its potential to treat various forms of cancer.
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is dedicated to delivering innovative products for the treatment of patients with cancer. The company’s research platform is dominated by two major programs: DNA/RNA-based medicines and small molecules. Genasense(R) (oblimersen sodium) Injection is the company’s lead compound from its DNA/RNA medicines program.
Genta is currently recruiting patients with advanced melanoma for the AGENDA Trial. Ganite(R) (gallium nitrate injection) is the company’s leading drug in its small molecule program, and is being exclusively marketed in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration.
Let us hear your thoughts below:
